Yale Medicine

Yes—some oral GLP-1 drugs work, but the best-supported ones are FDA-approved or in late-stage trials, not most compounded “drops” or tablets. In clinical studies, oral semaglutide and orforglipron have produced meaningful weight loss and metabolic improvements, but injectable GLP-1s still tend to be a bit more effective overall in head-to-head and comparative data.[1][2][14] What the evidence shows: Oral semaglutide can produce substantial weight loss. Recent high-dose trials reported about 13.6% average weight loss over roughly 71 weeks, which is close to injectable semaglutide’s roughly 15% in comparable trials, though still slightly lower.[2][13] Orforglipron has also shown strong results. In phase 3 obesity data, participants lost about 7.8% to 12.4% of body weight depending on dose over 72 weeks, and other reports from later trials suggest results can approach the low-to-mid teens.[3][11] Injectables remain the benchmark. Yale Medicine notes that pills and injections work the same way biologically, but injections have a modest edge in trial results, and a meta-analysis found subcutaneous semaglutide produced greater HbA1c lowering than oral semaglutide.[2][14] For compounded GLP-1 drops or tablets, the evidence is much weaker: Experts quoted in recent coverage warn that compounded or non-approved GLP-1 pills have not been proven in large clinical trials for safety and effectiveness.[4] Oral peptide drugs can break down in digestion, so compounded versions may have variable formulations and absorption, which makes real-world performance less predictable.[4] A practical way to think about it: Option Does it work? Evidence strength Typical takeaway FDA-approved oral GLP-1 Yes Strong Can work well, though usually a bit less than injections[2][13][14] Injectable GLP-1 Yes Strongest Usually slightly more effective overall[2][14] Compounded oral GLP-1 drops/tablets Unclear Weak Not reliably proven; quality and absorption may vary[4] If you want the most reliable oral option, look for FDA-approved oral semaglutide or a GLP-1 oral agent that has completed phase 3 trials, rather than compounded products.[2][4][13]

Mentioned in position 1 of 1